{"id":382184,"date":"2020-11-16T16:04:31","date_gmt":"2020-11-16T21:04:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382184"},"modified":"2020-11-16T16:04:31","modified_gmt":"2020-11-16T21:04:31","slug":"aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WAYNE, Pa., Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings.<\/p>\n<p>A live audio webcast of the fireside chat may be accessed through the Events page under the Investors section of Aclaris\u2019 website, www.aclaristx.com. An archived version of the webcast will be available for 30 days.<\/p>\n<p>\n        <strong>About Aclaris Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&amp;D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.<\/p>\n<p>\n        <strong>Aclaris Contact<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DsMrWksNAL_-IXxeSKe_nQgqJ9Dov4MwUxS3BLnOmYfj-5TEVfFujmEovt5dkWz2u98AtwxneFzAOKGWIaaf3QGUMMqZ5GfAmlOectSGeDA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@aclaristx.com<\/a>\n      <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5c2a9f87-7fa4-4a32-aaa2-624b98c810e4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings. A live audio webcast of the fireside chat may be accessed through the Events page under the Investors section of Aclaris\u2019 website, www.aclaristx.com. An archived version of the webcast will be available for 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings. A live audio webcast of the fireside chat may be accessed through the Events page under the Investors section of Aclaris\u2019 website, www.aclaristx.com. An archived version of the webcast will be available for 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; Continue reading &quot;Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T21:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference\",\"datePublished\":\"2020-11-16T21:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":180,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\",\"datePublished\":\"2020-11-16T21:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","og_description":"WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings. A live audio webcast of the fireside chat may be accessed through the Events page under the Investors section of Aclaris\u2019 website, www.aclaristx.com. An archived version of the webcast will be available for 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; Continue reading \"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T21:04:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference","datePublished":"2020-11-16T21:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":180,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/","name":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=","datePublished":"2020-11-16T21:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4Njg2MCMzODI3MDQ5IzIwMjAxODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}